1266 results found
Palmer E, Tyacke R, Sastre M, et al., 2019, Alcohol Hangover: Underlying Biochemical, Inflammatory and Neurochemical Mechanisms., Alcohol Alcohol
AIM: To review current alcohol hangover research in animals and humans and evaluate key evidence for contributing biological factors. METHOD: Narrative review with alcohol hangover defined as the state the day after a single episode of heavy drinking, when the alcohol concentration in the blood approaches zero. RESULTS: Many of the human studies of hangover are not well controlled, with subjects consuming different concentrations of alcohol over variable time periods and evaluation not blinded. Also, studies have measured different symptoms and use varying methods of measurement. Animal studies show variations with respect to the route of administration (intragastric or intraperitoneal), the behavioural tests utilised and discrepancy in the timepoint used for hangover onset. Human studies have the advantage over animal models of being able to assess subjective hangover severity and its correlation with specific behaviours and/or biochemical markers. However, animal models provide valuable insight into the neural mechanisms of hangover. Despite such limitations, several hangover models have identified pathological changes which correlate with the hangover state. We review studies examining the contribution of alcohol's metabolites, neurotransmitter changes with particular reference to glutamate, neuroinflammation and ingested congeners to hangover severity. CONCLUSION: Alcohol metabolites, neurotransmitter alterations, inflammatory factors and mitochondrial dysfunction are the most likely factors in hangover pathology. Future research should aim to investigate the relationship between these factors and their causal role.
Nutt DJ, Gual A, Anderson P, et al., 2019, Why Less Is Always More in the Treatment of Alcohol Use Disorders., JAMA Psychiatry
Goodwin GM, Nutt D, 2019, Antidepressants; what's the beef?, ACTA NEUROPSYCHIATRICA, Vol: 31, Pages: 59-60, ISSN: 1601-5215
Durant CF, Paterson LM, Turton S, et al., 2018, Using Baclofen to Explore GABA-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures, FRONTIERS IN PSYCHIATRY, Vol: 9, ISSN: 1664-0640
Nestor LJ, Paterson LM, Murphy A, et al., 2018, Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals., Eur J Neurosci
Identifying key neural substrates in addiction disorders for targeted drug development remains a major challenge for clinical neuroscience. One emerging target is the opioid system, where substance-dependent populations demonstrate prefrontal opioid dysregulation that predicts impulsivity and relapse. This may suggest that disturbances to the prefrontal opioid system could confer a risk for relapse in addiction due to weakened 'top-down' control over impulsive behaviour. Naltrexone is currently licensed for alcohol dependence and is also used clinically for impulse control disorders. Using a go/no-go (GNG) task, we examined the effects of acute naltrexone on the neural correlates of successful motor impulse control in abstinent alcoholics (AUD), abstinent polysubstance-dependent (poly-SUD) individuals and controls during a randomised double blind placebo controlled fMRI study. In the absence of any differences on GNG task performance, the AUD group showed a significantly greater BOLD response compared to the control group in lateral and medial prefrontal regions during both placebo and naltrexone treatments; effects that were positively correlated with alcohol abstinence. There was also a dissociation in the positive modulating effects of naltrexone in the orbitofrontal cortex (OFC) and anterior insula cortex (AIC) of the AUD and poly-SUD groups respectively. Self-reported trait impulsivity in the poly-SUD group also predicted the effect of naltrexone in the AIC. These results suggest that acute naltrexone differentially amplifies neural responses within two distinct regions of a salience network during successful motor impulse control in abstinent AUD and poly-SUD groups, which are predicted by trait impulsivity in the poly-SUD group.
Haijen ECHM, Kaelen M, Roseman L, et al., 2018, Predicting Responses to Psychedelics: A Prospective Study, FRONTIERS IN PHARMACOLOGY, Vol: 9, ISSN: 1663-9812
Timmermann C, Spriggs MJ, Kaelen M, et al., 2018, LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm, NEUROPHARMACOLOGY, Vol: 142, Pages: 251-262, ISSN: 0028-3908
Nutt D, Robbins T, Hayes A, 2018, THuNDRous news for human dopamine researchers: A selective dopamine D1 receptor antagonist will soon be available for clinical research, JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 32, Pages: 1153-1154, ISSN: 0269-8811
Rucker JJH, Iliff J, Nutt DJ, 2018, Psychiatry & the psychedelic drugs. Past, present & future, NEUROPHARMACOLOGY, Vol: 142, Pages: 200-218, ISSN: 0028-3908
Erritzoe D, Roseman L, Nour MM, et al., 2018, Effects of psilocybin therapy on personality structure, ACTA PSYCHIATRICA SCANDINAVICA, Vol: 138, Pages: 368-378, ISSN: 0001-690X
Roseman L, Demetriou L, Wall MB, et al., 2018, Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression, NEUROPHARMACOLOGY, Vol: 142, Pages: 263-269, ISSN: 0028-3908
Horder J, Andersson M, Mendez MA, et al., 2018, GABA(A) receptor availability is not altered in adults with autism spectrum disorder or in mouse models, SCIENCE TRANSLATIONAL MEDICINE, Vol: 10, ISSN: 1946-6234
Tyacke RJ, Myers JFM, Venkataraman A, et al., 2018, Evaluation of C-11-BU99008, a PET Ligand for the Imidazoline(2) Binding Site in Human Brain, JOURNAL OF NUCLEAR MEDICINE, Vol: 59, Pages: 1597-1602, ISSN: 0161-5505
Freeman TP, Mehta MA, Neill JC, et al., 2018, Restrictions on drugs with medical value: Moving beyond stalemate, JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 32, Pages: 1053-1055, ISSN: 0269-8811
Rogeberg O, Blomkvist AW, Nutt D, 2018, CANNABIS AND OPIOID OVERDOSES: TIME TO MOVE ON AND EXAMINE POTENTIAL MECHANISMS, ADDICTION, Vol: 113, Pages: 1551-1552, ISSN: 0965-2140
Venkataraman AV, Keat N, Myers JF, et al., 2018, First evaluation of PET-based human biodistribution and radiation dosimetry of C-11-BU99008, a tracer for imaging the imidazoline(2) binding site, EJNMMI RESEARCH, Vol: 8, ISSN: 2191-219X
Calsolaro V, Mayers J, Fan Z, et al., 2018, Evaluation of novel astrocyte marker [11C]BU99008 PET in Alzheimer’s disease: a Dementia Platform U.K. experimental medicine study, Alzheimer's and Dementia, Vol: 14, Pages: P842-P843, ISSN: 1552-5260
Fan Z, Calsolaro V, Mayers J, et al., 2018, Relationship between astrocyte activation using [11C]BU99008 PET, glucose metabolism and amyloid in Alzheimer’s disease: a Dementia Platform UK experimental medicine study, Alzheimer's and Dementia, Vol: 14, Pages: P1640-P1640, ISSN: 1552-5260
van den Brink W, Addolorato G, Aubin H-J, et al., 2018, Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level, ADDICTION BIOLOGY, Vol: 23, Pages: 969-986, ISSN: 1355-6215
Turton S, Myers JF, Mick I, et al., 2018, Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals., Mol Psychiatry
Addiction has been proposed as a 'reward deficient' state, which is compensated for with substance use. There is growing evidence of dysregulation in the opioid system, which plays a key role in reward, underpinning addiction. Low levels of endogenous opioids are implicated in vulnerability for developing alcohol dependence (AD) and high mu-opioid receptor (MOR) availability in early abstinence is associated with greater craving. This high MOR availability is proposed to be the target of opioid antagonist medication to prevent relapse. However, changes in endogenous opioid tone in AD are poorly characterised and are important to understand as opioid antagonists do not help everyone with AD. We used [11C]carfentanil, a selective MOR agonist positron emission tomography (PET) radioligand, to investigate endogenous opioid tone in AD for the first time. We recruited 13 abstinent male AD and 15 control participants who underwent two [11C]carfentanil PET scans, one before and one 3 h following a 0.5 mg/kg oral dose of dexamphetamine to measure baseline MOR availability and endogenous opioid release. We found significantly blunted dexamphetamine-induced opioid release in 5 out of 10 regions-of-interest including insula, frontal lobe and putamen in AD compared with controls, but no significantly higher MOR availability AD participants compared with HC in any region. This study is comparable to our previous results of blunted dexamphetamine-induced opioid release in gambling disorder, suggesting that this dysregulation in opioid tone is common to both behavioural and substance addictions.
Rogeberg O, Bergsvik D, Phillips LD, et al., 2018, A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation, INTERNATIONAL JOURNAL OF DRUG POLICY, Vol: 56, Pages: 144-152, ISSN: 0955-3959
Gabay AS, Carhart-Harris RL, Mazibuko N, et al., 2018, Psilocybin and MDMA reduce costly punishment in the Ultimatum Game, SCIENTIFIC REPORTS, Vol: 8, ISSN: 2045-2322
Kaelen M, Giribaldi B, Raine J, et al., 2018, The hidden therapist: evidence for a central role of music in psychedelic therapy (vol 235, pg 505, 2018), PSYCHOPHARMACOLOGY, Vol: 235, Pages: 1623-1623, ISSN: 0033-3158
Carrillo F, Sigman M, Fernandez Slezak D, et al., 2018, Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression, JOURNAL OF AFFECTIVE DISORDERS, Vol: 230, Pages: 84-86, ISSN: 0165-0327
Dukart J, Holiga S, Chatham C, et al., 2018, Cerebral blood flow predicts differential neurotransmitter activity, SCIENTIFIC REPORTS, Vol: 8, ISSN: 2045-2322
Curran HV, Nutt D, de Wit H, 2018, Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation, PSYCHOPHARMACOLOGY, Vol: 235, Pages: 373-375, ISSN: 0033-3158
Carhart-Harris RL, Bolstridge M, Day CMJ, et al., 2018, Psilocybin with psychological support for treatment-resistant depression: six-month follow-up, PSYCHOPHARMACOLOGY, Vol: 235, Pages: 399-408, ISSN: 0033-3158
Kaelen M, Giribaldi B, Raine J, et al., 2018, The hidden therapist: evidence for a central role of music in psychedelic therapy, PSYCHOPHARMACOLOGY, Vol: 235, Pages: 505-519, ISSN: 0033-3158
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.